Phylogenetic clustering of surveillance drug resistance mutations in HIV-1 among patients naïve to highly active antiretroviral therapy (HAART) and those who are non-adherent to treatment

未接受高效抗逆转录病毒治疗 (HAART) 和不坚持治疗的患者中 HIV-1 耐药突变监测的系统发育聚类

• 批准号: 367258
• 负责人: McLaughlin Angela M
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-12-01 至 2017-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=367258&lang=en
• 关键词: Acquired Immune Deficiency Syndrome (Aids); Downtown Eastside (Dtes) Vancouver; Genomic Epidemiology; Highly Active Antiretroviral Therapy (Haart); Human Immunodeficiency Virus (Hiv); Infectious Disease Transmission; Naive Patients; Phylogenetic Clusterin

Highly active antiretroviral therapy (HAART) has helped to prolong survival for people living with human immunodeficiency virus (HIV) and hamper its progression to acquired immunodeficiency disease. HAART is a customized combination of antiretroviral drug

高效抗逆转录病毒疗法（HAART）有助于延长人类免疫缺陷病毒（HIV）感染者的生存期，并阻止其发展为获得性免疫缺陷疾病。HAART是一种定制的抗逆转录病毒药物组合，